Trial Profile
A Phase II Study of Single Agent Topoisomerase-I Inhibitor Polymer Conjugate, Etirinotecan Pegol (NKTR-102), in Patients With Relapsed Small Cell Lung Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Etirinotecan pegol (Primary)
- Indications Small cell lung cancer
- Focus Therapeutic Use
- 31 Dec 2019 Planned End Date changed from 18 Dec 2019 to 18 Feb 2020.
- 04 Oct 2019 Planned End Date changed from 18 Sep 2019 to 18 Dec 2019.
- 12 Aug 2019 Planned End Date changed from 18 Jul 2018 to 18 Sep 2019.